Fate Therapeutics Inc (NAS:FATE)
$ 3.76 0.1 (2.73%) Market Cap: 428.01 Mil Enterprise Value: 135.15 Mil PE Ratio: 0 PB Ratio: 1.01 GF Score: 58/100

Q4 2018 Fate Therapeutics Inc Earnings Call Transcript

Mar 05, 2019 / 10:00PM GMT
Release Date Price: $16.03 (-1.05%)
Operator

Welcome to the Fate Therapeutics Fourth Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on the Investors & Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded.

I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, CFO, President, Treasurer, Secretary & Director

Thank you. Good afternoon, and thanks, everyone, for joining us for the Fate Therapeutics Fourth Quarter 2018 Financial Results Call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the Investors & Media section of our website under Press Releases. In addition, our Form 10-K for the year ended December 31, 2018, was filed shortly thereafter and can be found on the Investors & Media section of our website under Financial Information.

Before we begin, I would like to remind everyone that except for statements of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot